中国国家药监局药品审评中心(CDE)官网公示,维立志博生物申报的1类新药注射用LBL-047获批临床,拟开发治疗系统性红斑狼疮。公开资料显示,这是一款新型抗BDCA2/TACI双特异性融合蛋白。LBL-047是维立志博的临床前管线,是将工程化改造的跨膜激活剂及钙调亲环素配体相互作用分子(TACI)结构域和去岩藻糖的抗血液树突状细胞抗原2(BDCA2)人源化单克隆抗体融合,得到的抗BDCA2/...
Source Link中国国家药监局药品审评中心(CDE)官网公示,维立志博生物申报的1类新药注射用LBL-047获批临床,拟开发治疗系统性红斑狼疮。公开资料显示,这是一款新型抗BDCA2/TACI双特异性融合蛋白。LBL-047是维立志博的临床前管线,是将工程化改造的跨膜激活剂及钙调亲环素配体相互作用分子(TACI)结构域和去岩藻糖的抗血液树突状细胞抗原2(BDCA2)人源化单克隆抗体融合,得到的抗BDCA2/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.